Neurotoxicity of cobalt

Human and Experimental Toxicology

Volumn 31, Issue 5, 2012, Pages 421-437

  Catalani, S ^a   Rizzetti, M C ^a   Padovani, A ^a   Apostoli, P ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

cobalt; iatrogenic exposure; neurotoxicology; occupational exposure; prosthesis

Indexed keywords

ALLOY; BIOLOGICAL MARKER; CHROMIUM; CISPLATIN; COBALT; COBALT CHLORIDE; GLASS; METAL; METAL OXIDE; MITOCHONDRIAL DNA; MOLYBDENUM; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; POLYETHYLENE; REACTIVE OXYGEN METABOLITE; TITANIUM;

AIR POLLUTANT; ANEMIA; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COCHLEA; DEMYELINATION; DEVICES; DIETARY INTAKE; DRUG WITHDRAWAL; DUST; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HAIR CELL; HEADACHE; HEAVY METAL POISONING; HIP ARTHROPLASTY; HIP PROSTHESIS; HUMAN; IATROGENIC DISEASE; INDUSTRIAL HYGIENE; INDUSTRIAL WORKER; INFECTION; LEBER HEREDITARY OPTIC NEUROPATHY; LONG TERM CARE; LONG TERM EXPOSURE; MEMORY DISORDER; METAL BINDING; METAL IMPLANTATION; METALLURGY; NEPHRITIS; NERVE BIOPSY; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; OPTIC NERVE ATROPHY; OTOTOXICITY; PANCYTOPENIA; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROSTHESIS; PROSTHESIS MATERIAL; RETINOPATHY; REVIEW; SENSORIMOTOR NEUROPATHY; TARGET CELL; TINNITUS; TOTAL HIP PROSTHESIS; TOXICOKINETICS; TREATMENT OUTCOME; TREMOR; UREMIA; URINE LEVEL; VERTIGO; VISUAL IMPAIRMENT; WORKPLACE;

COBALT; HUMANS; NEUROTOXICITY SYNDROMES; OCCUPATIONAL EXPOSURE; PROSTHESES AND IMPLANTS;

EID: 84864203791     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327111414280     Document Type: Review

References (130)

1. Domingo JL. Cobalt in the environment and its toxicological implications. Rev Environ Contam Toxicol. 1989 ; 108: 105-132 (Pubitemid 19012138)
2. Lauwerys R, Lison D. Health risks associated with cobalt exposure-an overview. Occup Environ Med. 1994 ; 51: 447-450
3. Barceloux DG. Cobalt. J Toxicol Clin Toxicol. 1999 ; 37: 201-206
4. Angerer J, Heinrich R Handbook on the toxicology of metals. 2 nd ed. New York, NY: Elsevier Science, 1986, pp.251-261. Friberg L Nordberg GF Vouk VB, ed. New York, NY: Elsevier Science ; 1986: 251-261.
5. Lison D Handbook on the toxicology of metals. 3 rd ed. Burlington, USA: Elsevier, 2007, pp.511-528. Norberg GF Fowler BA Norberg M Friberg LT, ed. Burlington, USA: Elsevier ; 2007: 511-528.
6. Smith HIC, Carson BL. An appraisal of environmental exposure. Ann Arbor, MI: Ann Arbor Science ; 1981 :
7. Some Other Halogenated Compounds. Cobalt and Cobalt Compounds Monographs on the Evaluation of Carcinogenic Risks to Humans IARC: Lyon ; 1991 :
8. Lyon ; 2006 :
9. Gardner FH. The use of cobalt chloride in anaemia associated with chronic renal disease. J Lab Clin Med. 1953 ; 49: 56-63
10. Schirrmacher UOE. Case of cobalt poisoning. Br Med J. 1967 ; 1: 544-545
11. Licht A, Oliver M, Rachmilewitz EA. Optic atrophy following treatment with cobalt chloride in a patient with pancytopenia and hypercellular marrow. Isr J Med Sci. 1972 ; 8: 61-66
12. Jordan C, Whitman RD, Harbut M. Memory deficits in workers suffering from hard metal disease. Toxicol Lett. 1990 ; 54: 241-243
13. Meecham HM, Humphrey P. Industrial exposure to cobalt causing optic atrophy and nerve deafness: a case report. J Neurol Neurosurg Psychiatry. 1991 ; 54: 374-375
14. Megaterio S, Galetto F, Alossa E, Capretto S. Systemic effects of ionic release in wear of prosthetic head: a case report. Giornale Italiano di Ortopedia e Traumatologia. 2001 ; 27: 173-175
15. Steens W, Von Foerster G, Katzer A. Severe cobalt poisoning with loss of sight after ceramic-metal pairing in a hip-a case report. Acta Orthop. 2006 ; 77: 830-832 (Pubitemid 44521928)
16. Oldenburg M, Wegner R, Baur X. Severe cobalt intoxication due to prosthesis wear in repeated total hip arthroplasty. J Arthroplasty. 2009 ; 24: 825e15-825e20
17. Rizzetti MC, Liberini P, Zarattini G. Loss of sight and sound Could it be the hip?. Lancet. 2009 ; 1052: 373
18. Ikeda T, Takahashi K, Kabata T. Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement. Muscle Nerve. 2010 ; 42: 140-143
19. Tower SS. Arthroprosthetic cobaltism: neurological and cardiac manifestations in two patients with metal-on-metal arthroplasty: a case report. J Bone Joint Surg. 2010 ; 92: 1-5
20. Medicines and Healthcare Products Regulatory Agency UK.; MDA/2010/033: All metal-on-metal hip replacements. MDA/2010/033 Issued: 22 April 2010. http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/ CON079157 (accessed 10 June 2010).
21. Tower SS. Arthroprosthetic cobaltism: identification of the at-risk patient. Alaska Med. 2010 ; 52: 28-32
22. Agency for toxic substances and disease registry. Cobalt. http://www.atsdr.cdc.gov/ToxProfiles/tp33.pdf (2004, accessed 20 March 2010).
23. Broding HC, Michalke B, Göen T, Drexler H. Comparison between exhaled breath condensate analysis as a marker for cobalt and tungsten exposure and biomonitoring in workers of a hard metal alloy processing plant. Int Arch Occup Environ Health. 2009 ; 82: 565-573
24. Apostoli P, Porru S, Alessio L. Urinary cobalt excretion in short time occupational exposure to cobalt powders. Sci Total Environ. 1994 ; 150: 129-132 (Pubitemid 24210695)
25. Varela-Moreiras G, Murphy MM, Scott JM. Cobalamin, folic acid, and homocysteine. Nutr Rev. 2009 ; 67: S69 - S72
26. Larese Filon F, Maina G, Adami G, et al. In vitro percutaneous absorption of cobalt. Int Arch Occup Environ Health. 2004 ; 77: 85-89 (Pubitemid 38263397)
27. Scansetti G, Botta GC, Spinelli P. Absorption and excretion of cobalt in the hard metal industry. Sci Total Environ. 1994 ; 150: 141-144 (Pubitemid 24210697)
28. Swennen B, Buchet JP, Stánescu D. Epidemiological survey of workers exposed to cobalt oxides, cobalt salts, and cobalt metal. Br J Ind Med. 1993 ; 50: 835-842 (Pubitemid 23293488)
29. Scansetti G, Maina G, Botta GC. Exposure to cobalt and nickel in the hard-metal production industry. Int Arch Occup Environ Health. 1998 ; 71: 60-63 (Pubitemid 28130012)
30. Cincinnati, USA: ACGIH ; 2010 :
31. Weinheim: Wiley-VCH ; 2006 :
32. Alexanderson R, Lidums V.. Studies on effects of exposure to cobalt. Concentration of cobalt in blood and urine as indicators of exposure. Arbete Och Halsa. 1979 ; 8: 1-23
33. Morgan LG. A study into the health and mortality of men exposed to cobalt and oxides. J Soc Occup Med. 1983 ; 33: 181-186 (Pubitemid 14210105)
34. Angerer J, Heinrich R, Felixberger RX, et al Verhandlungen der deutschen gesellschaft für Arbeitsmedizin Stuttgart Gentner Verlag. 1984 :
35. Pellet F, Perdrix A, Vincent M, Mallion JM. Dosage biologique du cobalt urinarire. Arch Mal Professionnelles. 1984 ; 45: 81-85
36. Verhandlungen der deutschen gesellschaft für. Hartung M Schaller KH, ed. Arbeitsmedizin: Stuttgart Gentner Verlag ; 1984 :
37. Ichikawa Y, Kusaka Y, Goto S. Biological monitoring of cobalt exposure, based on cobalt concentrations in blood and urine. Int Arch Occup Environ Health. 1985 ; 55: 269-276 (Pubitemid 15074480)
38. Posma FD, Dijstelberger SK. Heavy Metals In The Environment TD Lekkas TD Edinburgh CEP consultants LTD.. 1985 ;:
39. Lison D, Buchet JP, Swennen B. Biological monitoring of workers exposed to cobalt metal, salt, oxides, and hard metal dust. Occup Environ Med. 1994 ; 51: 447-450 (Pubitemid 24210980)
40. Yokota K, Johyama Y, Kunitani Y. Urinary elimination of nickel and cobalt in relation to airborne nickel and cobalt exposures in a battery plant. Int Arch Occup Environ Health. 2007 ; 80: 527-531 (Pubitemid 46691996)
41. De Palma G, Manini P, Sarnico M. Biological monitoring of tungsten (and cobalt) in workers of a hard metal alloy industry. Int Arch Occup Environ Health. 2010 ; 83: 173-181
42. Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, July 2010. Centers for Disease Control and Prevention, Atlanta. http://www.cdc.gov/exposurereport/ (accessed 30 September 2010).
43. Christensen JM, Poulsen OM. A 1982-1992 surveillance programme on Danish pottery painters Biological levels and health effects following exposure to soluble or insoluble cobalt compounds in cobalt blue dyes. Sci Total Environ. 1994 ; 150: 95-104 (Pubitemid 24210690)
44. Sunderman FW, Hopfer SM, Swift T. Cobalt, chromium and nickel concentrations in body fluids of patients with porous coated knee or hip prostheses. J Orthop Res. 1989 ; 7: 307-315 (Pubitemid 19132848)
45. Vendittoli PA, Ganapathi M, Lavigne M. Blood and urine metal ion levels in young and active patients after Birmingham hip resurfacing arthroplasty. J Bone Joint Surg Br. 2007 ; 89: 989-990
46. Grübl A, Marker M, Brodner W. Long-term follow-up of metal-on-metal total hip replacement. J Orthop Res. 2007 ; 25: 841-848 (Pubitemid 47046430)
47. Schaffer AW, Pilger A, Engelhardt C. Increased blood cobalt and chromium after total hip replacement. J Toxicol Clin Toxicol. 1999 ; 37: 839-844 (Pubitemid 30013372)
48. Harding I, Bonomo A, Crawford R. Serum levels of cobalt and chromium in a complex modular total hip arthroplasty system. J Arthroplasty. 2002 ; 17: 893-895
49. Skipor AK, Campbell PA, Patterson LM. Serum and urine metal levels in patients with metal-on-metal surface arthroplasty. J Mater Sci Mater Med. 2002 ; 13: 1227-1234 (Pubitemid 36169463)
50. Clarke MT, Lee PT, Arora A, Villar RN. Levels of metal ions after small- and large-diameter metal-on-metal hip arthroplasty. J Bone Joint Surg Br. 2003 ; 85: 913-917 (Pubitemid 36986860)
51. Keel JB, Kuster MS. Massive wear of an incompatible metal-on-metal articulation in total hip arthroplasty. J Arthroplasty. 2004 ; 19: 638-642 (Pubitemid 38993195)
52. Back DL, Young D, Shimmin AJ. How do serum cobalt and chromium levels change after metal-on-metal hip resurfacing?. Clin Orthop Relat Res. 2005 ; 438: 177-181 (Pubitemid 41254334)
53. Rasquinha VJ, Ranawat CS, Weiskopf J. Serum metal levels and bearing surfaces in total hip arthroplasty. J Arthroplasty. 2006 ; 21: 47-52 (Pubitemid 44293261)
54. Milosev I, Pisot V, Campbell P. Serum levels of cobalt and chromium in patients with Sikomet metal-metal total hip replacements. J Orthop Res. 2005 ; 23: 526-535 (Pubitemid 40631322)
55. Iavicoli I, Falcone G, Alessandrelli M. The release of metals from metal-on-metal surface arthroplasty of the hip. J Trace Elem Med Biol. 2006 ; 20: 25-31
56. Sauvé P, Mountney J, Khan T. Metal ion levels after metal-on-metal Ring total hip replacement: a 30-year follow-up study. J Bone Joint Surg Br. 2007 ; 89: 586-590 (Pubitemid 46958763)
57. Luetzner J, Krummenauer F, Lengel AM. Serum metal ion exposure after total knee arthroplasty. Clin Orthop Relat Res. 2007 ; 461: 136-142 (Pubitemid 47344106)
58. De Haan R, Campbell P, Reid S. Metal ion levels in atriathlete with a metal-on-metal resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2007 ; 89: 538-541 (Pubitemid 46851138)
59. Antoniou J, Zukor DJ, Mwale F. Metal ion levels in the blood of patients after hip resurfacing: a comparison between twenty-height and thirty-six millimeter-head metal-on-metal prostheses. J Bone Joint Surg. 2008 ; 90: 142-148
60. Sarmiento-González A, Marchante-Gayón JM, Tejerina-Lobo JM, et al. High-resolution ICP-MS determination of Ti, V, Cr, Co, Ni, and Mo in human blood and urine of patients implanted with a hip or knee prosthesis. Anal Bioanal Chem. 2008 ; 391: 2583-2589
61. Heisel C, Streich N, Krachler M. Characterization of the running-in period in total hip resurfacing arthroplasty: an in vivo and in vitro metal ion analysis. J Bone Joint Surg. 2008 ; 90: 125-133
62. Walter LR, Marel E, Harbury R, Wearne J. Distribution of chromium and cobalt ions in various blood fractions after resurfacing hip arthroplasty. J Arthroplasty. 2008 ; 23: 814-821
63. Isaac GH, Siebel T, Oakeshott RD. Changes in whole blood metal ion levels following resurfacing: serial measurements in a multi-centre study. Hip Int. 2009 ; 19: 330-337
64. Von Schewelov T, Sanzén L. Catastrophic failure due to aggressive metallosis 4 years after hip resurfacing in a woman in her forties-a case report. Acta Orthop. 2010 ; 81: 402-404
65. Lhotka C, Szekeres T, Steffan I. Four-year study of cobalt and chromium blood levels in patients managed with two different metal-on-metal total hip replacements. J Orthop Res. 2003 ; 21: 189-195 (Pubitemid 36322536)
66. Maezawa K, Nozawa M, Hirose T. Cobalt and chromium concentrations in patients with metal-on-metal and other cementless total hip arthroplasty. Arch Orthop Trauma Surg. 2002 ; 122: 283-287 (Pubitemid 36067920)
67. Schmidt EM, Bak MJ, Hambrecht FT. Feasibility of a visual prosthesis for the blind based on intracortical microstimulation of the visual cortex. Brain. 1996 ; 119: 507-522 (Pubitemid 26149365)
68. Amstutz HC, Beaule PE, Dorey FJ. Metal-on-metal hybrid surface arthroplasty: two to six-year follow-up study. J Bone Joint Surg. 2004 ; 86: 28-39 (Pubitemid 38057333)
69. Basle MF, Bertrand G, Guyetant S. Migration of metal and polyethylene particles from articular prostheses may generate lymphadenopathy with histiocytosis. J Biomed Mater Res. 1996 ; 30: 157-163
70. Szuszczewicz ES, Schmalzried TP, Petersen TD. Progressive bilateral pelvic osteolysis in a patient with McKee-Farrar metal-metal total hip prostheses. J Arthroplasty. 1997 ; 12: 819-824 (Pubitemid 27452617)
71. Matziolis G, Perka C, Disch A. Massive metallosis after revision of a fractured ceramic head onto a metal head. Arch Orthop Trauma Surg. 2003 ; 123: 48-50 (Pubitemid 36747756)
72. Gallinaro P, Piolatto G. Blind and deaf after total hip replacement? author reply of Rizzetti MC, Liberini P, Zarattini G, Catalani S, Pazzaglia U, Apostoli P, Padovani. Lancet. 2009 1944 ; 373 :
73. Sadler PJ, Tucker A, Viles JH. Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. Eur J Biochem. 1994 ; 220: 193-200 (Pubitemid 24067569)
74. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. Am J Emerg Med. 2000 ; 19: 311-315
75. Bar-Or D, Rael LT, Bar-Or R. The cobalt-albumin binding assay: insights into its mode of action. Clin Chim Acta. 2008 ; 387: 120-127 (Pubitemid 350050944)
76. Bar-Or D, Rael LT, Lau EP. An analog of the human albumin N-terminus (Asp-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species. Biochem Biophys Res Commun. 2001 ; 284: 856-862 (Pubitemid 32926747)
77. Mothes E, Faller P. Evidence that the principal CoII-binding site in human serum albumin is not at the N-terminus: implication on the albumin cobalt binding test for detecting myocardial ischemia. Biochemistry. 2007 ; 46: 2267-2274 (Pubitemid 46355336)
78. Lippi G, Brocco G, Salvagno GL. High-workload endurance training may increase serum ischemia-modified albumin concentrations. Clin Chem Lab Med. 2005 ; 43: 741-744 (Pubitemid 41461180)
79. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. Can J Emerg Med. 2006 ; 8: 27-31
80. Govender R, De Greef J, Delport R. Biological variation of ischaemia-modified albumin in healthy subjects. Cardiovasc J Afr. 2008 ; 19: 141-144
81. Bhagavan NV, Lai EM, Rios PA. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003 ; 49: 581-585 (Pubitemid 36379523)
82. Sheat JM, Peach RJ, George PM. Rapid detection and initial characterization albumin. Clin Chem. 1991 ; 37: 1221-1224
83. Sun H, Li H, Sadler PJ. Transferrin as a metal ion mediator. Chem Rev. 1999 ; 99: 2817-2842
84. Smith TAD. Human serum transferrin cobalt complex: stability and cellular uptake of cobalt. Bioorg Med Chem. 2005 ; 13: 4576-4579 (Pubitemid 40813245)
85. Moshtaghie AA, Badii A, Mohammadian T. The comparative study of binding characteristics of cobalt and iron to human serum transferrin. J Res Med Sci. 2004 ; 6: 250-254
86. Virginio C, Church D, North RA, Surprenant A. Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacology. 1997 ; 36: 1285-1294 (Pubitemid 27465616)
87. Picard V, Govoni G, Jabado N, Gros P. Nramp2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other divalent cations into a calcein-accessible cytoplasmic pool. J Biol Chem. 2000 ; 275: 35738-35745
88. Forbes J.R., Gros P. Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane. Blood. 2003 ; 102: 1884-1892 (Pubitemid 37022588)
89. Howitt J, Putz U, Lackovic J. Divalent metal transporter 1 (DMT1) regulation by Ndfip1 prevents metal toxicity in human neurons. Proc Natl Acad Sci U S A. 2009 ; 106: 15489-15494
90. Himeno S, Yanagiya T, Fujishiro H. The role of zinc transporters in cadmium and manganese transport in mammalian cells. Biochimie. 2009 ; 91: 1218-1222
91. Wang G, Hazra TK, Mitra S. Mitochondrial DNA damage and a hypoxic response are induced by CoCl(2) in rat neuronal PC12 cells. Nucleic Acids Res. 2000 ; 28: 2135-2140 (Pubitemid 30255536)
92. Olivieri G, Hess C, Savaskan E. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res. 2001 ; 31: 320-325 (Pubitemid 33032947)
93. Yang SJ, Pyen J, Lee I. Cobalt chloride induced apoptosis and extracellular signal-regulated protein kinase 1/2 activation in rat C6 glioma cells. J Biochem Mol Biol. 2004 ; 37: 480-486 (Pubitemid 39207683)
94. Zou W, Zeng J, Zhuo M. Involvement of caspase-3 and p38 mitogen-activated protein kinase in cobalt chloride-induced apoptosis in PC12 cells. J Neurosci Res. 2002 ; 67: 837-843 (Pubitemid 34226297)
95. Zou W, Yan M, Xu W. Cobalt chloride induces PC12 cells apoptosis through reactive oxygen species and accompanied by AP-1 activation. J Neurosci Res. 2001 ; 64: 646-653 (Pubitemid 32520687)
96. Araya J, Maruyama M, Inoue A. Inhibition of proteasome activity is involved in cobalt-induced apoptosis of human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2002 ; 283: L849 - L858
97. Graham RM, Frazier DP, Thompson JW. A unique pathway of cardiac myocyte death caused by hypoxia-acidosis. J Exp Biol. 2004 ; 207: 3189-3200 (Pubitemid 39275293)
98. Lee SG, Lee H, Rho HM. Transcriptional repression of the human p53 gene by cobalt chloride mimicking hypoxia. FEBS Lett. 2001 ; 507: 259-263 (Pubitemid 33030246)
99. Czarnota M, Whitman D, Berman R. Activity and passive-avoidance learning in cobalt-injected rats. Int J Neurosci. 1998 ; 93: 29-33
100. Hasan M, Ali S, Anwar J. Cobalt-induced depletion of dopamine, norepinephrine & 5-hydroxytryptamine concentration in different regions of the rat brain. Indian J Exp Biol. 1980 ; 18: 1051-1053
101. Gerber U, Gähwiler BH. Cobalt blocks postsynaptic responses induced by neurotransmitters in the hippocampus in vitro. Neurosci Lett. 1991 ; 134: 53-56
102. Alagna G, D'Acquino S. Alterazioni oculari da cloruro di cobalto. Archivio di Ottalmologia. 1956 ; 60: 5-29
103. Monies A, Prost M. Experimental studies on lesions of eye tissues in cobalt intoxication. Klinika Oczna. 1994 ; 96: 135-139
104. Prasad RS, Kodali VR, Khuraijam GS. Acute confusion and blindness from quinine toxicity. Eur J Emerg Med. 2003 ; 10: 353-356
105. Fox DA, Rubinstein SD, Hsu P.. Developmental lead exposure inhibits adult rat retinal, but not kidney, Na+,K(+)-ATPase. Toxicol Appl Pharmacol. 1991 ; 109: 482-493
106. Tsao K, Aitken PA, Johns DR. Smoking as an aetiological factor in a pedigree with Leber's hereditary optic neuropathy. Br J Ophthalmol. 1999 ; 83: 577-581 (Pubitemid 29213132)
107. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retinal Eye Res. 2004 ; 23: 53-89 (Pubitemid 38177172)
108. Karovic O, Tonazzini I, Rebola N. Toxic effects of cobalt in primary cultures of mouse astrocytes: similarities with hypoxia and role of HIF-1alpha. Biochem Pharmacol. 2007 ; 73: 694-708 (Pubitemid 46161378)
109. Sharp FR, Ran R, Lu A. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx. 2004 ; 1: 26-35 (Pubitemid 46613775)
110. Wiesener MS, Maxwell PH. HIF and oxygen sensing; as important to life as the air we breathe?. Ann Med. 2003 ; 35: 183-190 (Pubitemid 36765231)
111. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006 ; 3: 177-185
112. Papandreou I, Cairns RA, Fontana L. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006 ; 3: 187-197
113. Fukuda R, Zhang H, Kim JW. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007 ; 129: 111-122 (Pubitemid 46507584)
114. Hirose K, Hockenberry DM, Rubel EW. Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. Hear Res. 1997 ; 104: 1-14 (Pubitemid 27092045)
115. Sha S, Taylor R, Forge A. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res. 2001 ; 155: 1-8 (Pubitemid 32401586)
116. Hirose K, Westrum LE, Cunningham DE, Rubel EW. Electron microscopy of degenerative changes in the chick basilar papilla after gentamicin exposure. J Comp Neurol. 2004 ; 470: 164-180 (Pubitemid 38160689)
117. Clerici WJ, DiMartino DL, Prasad MR. Direct effect of reactive oxygen species on cochlear outer hair cells. Hear Res. 1995 ; 84: 30-40
118. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin induced ototoxicity and prevention. Hear Res. 2007 ; 226: 157-167 (Pubitemid 46428033)
119. Lee JE, Nakagawa T, Kita T. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol. 2004 ; 124: 1131-1135 (Pubitemid 40051560)
120. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999 ; 15: 551-578 (Pubitemid 32250386)
121. Valko M, Rhodes CJ, Moncol J. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006 ; 160: 1-40 (Pubitemid 43227479)
122. Lewis CPL, Demedts M, Nemery B.. Indices of oxidative stress in hamster lung following exposure to cobalt(II) ions: In vivo and in vitro studies. Am J Respir Cell Mol Biol. 1991 ; 5: 163-169
123. Kasprzak KS, Zastawny TH, North SL. Oxidative DNA base damage in renal, hepatic, and pulmonary chromatin of rats after intraperitoneal injection of cobalt(II) acetate. Chem Res Toxicol. 1994 ; 7: 329-335 (Pubitemid 24150092)
124. Hoet PMH, Roesems G, Demedts MG, Nemery B. Activation of the hexose monophosphate shunt in rat type II pneumocytes as an early marker of oxidative stress caused by cobalt particles. Arch Toxicol. 2002 ; 76: 1-7 (Pubitemid 34209098)
125. Ivancsits S, Diem E, Pilger A, Rüdiger HW. Induction of 8-hydroxy-2'-deoxyguanosine by cobalt(II) and hydrogen peroxide in vitro. J Toxicol Environ Health A. 2002 ; 65: 665-676 (Pubitemid 34450692)
126. Peters U, Preisler-Adams S, Lanvers-Kaminsky C. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res. 2003 ; 23: 1249-1255 (Pubitemid 36754084)
127. Ghelli A, Porcelli AM, Zanna C. The background of mitochondrial DNA haplogroup J increases the sensitivity of Leber's hereditary optic neuropathy cells to 2,5-hexanedione toxicity. PLoS One. 2009 ; e7922: 4
128. Amati-Bonneau P, Milea D, Bonneau D. OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol. 2009 ; 41: 1855-1865
129. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999 ; 9: 69-92 (Pubitemid 29056521)
130. Hartung HP, Jung S, Stoll G. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol. 1992 ; 40: 197-210